MarketCapExport financials
Aclaris Therapeutics (ACRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aclaris Therapeutics Balance Sheet 2025-2011 | ACRS
Brief overview of Aclaris Therapeutics's assets and capital
The comparison uses five available annual reports from the 2021–2025 interval.
Assets fell from $251.2 million to $160.5 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities grew faster than assets: +6.5% versus -36.1%. A substantial part of expansion was externally funded.
The equity-to-assets ratio is 64.2%, compared with 78.6% five periods ago. The balance sheet has a substantial internal cushion.
The balance sheet holds more cash than interest-bearing debt; net debt is -$17.8 million, indicating minimal leverage.
The cash reserve occupies 12.4% of the balance sheet, previously 10.9%. It is one marker of short-term resilience.
The balance sheet includes a negative accumulated result of -$967.8 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
Aclaris Therapeutics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Aclaris Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-17.8 M | -22 M | -36.4 M | -43 M | -24.5 M | -10.8 M | -35.3 M | -26.5 M | -20.1 M | -30.2 M | -9.85 M | -10.8 M | -9.59 M | - | - |
Long Term Debt |
1.56 M | 2.12 M | 3.07 M | 1.57 M | 2.15 M | 10.7 M | - | 29.9 M | - | - | - | - | - | - | - |
Long Term Debt Current |
551 K | 481 K | 426 K | 684 K | 693 K | 603 K | 526 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
28.7 M | 33.2 M | 9.27 M | 35 M | 30.9 M | 18.3 M | 5.95 M | 33.1 M | 5.48 M | 372 K | - | 36.7 M | 23 M | - | - |
Total Current Liabilities |
28.6 M | 31.6 M | 31 M | 21.9 M | 22.9 M | 14.9 M | 22.4 M | 27.3 M | 12.8 M | 6.22 M | 1.56 M | - | - | - | - |
Total Liabilities |
57.4 M | 64.8 M | 40.2 M | 57 M | 53.9 M | 33.1 M | 28.4 M | 60.4 M | 18.2 M | 6.6 M | 1.56 M | 38.1 M | 23.4 M | - | - |
Deferred Revenue |
3.94 M | 3.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-968 M | -903 M | -771 M | -682 M | -595 M | -505 M | -454 M | -292 M | -159 M | -90.9 M | -42.8 M | -20.7 M | -9.17 M | - | - |
Total Assets |
160 M | 220 M | 197 M | 255 M | 251 M | 70.8 M | 98.3 M | 276 M | 244 M | 176 M | 94.1 M | 17.4 M | 14.2 M | - | - |
Cash and Cash Equivalents |
20 M | 24.6 M | 39.9 M | 45.3 M | 27.3 M | 22.1 M | 35.9 M | 57 M | 20.2 M | 30.2 M | 9.85 M | 10.8 M | 9.59 M | - | - |
Book Value |
103 M | 156 M | 157 M | 198 M | 197 M | 37.6 M | 69.9 M | 215 M | 225 M | 169 M | 92.5 M | -20.8 M | -9.16 M | - | - |
Total Shareholders Equity |
103 M | 156 M | 157 M | 198 M | 197 M | 37.6 M | 69.9 M | 215 M | 225 M | 169 M | 92.5 M | -20.8 M | -9.16 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Aclaris Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.1 M | 1.26 M | 1.42 M | 1.56 M | 1.71 M | 1.85 M | 1.99 M | 2.12 M | 2.24 M | 2.37 M | 2.97 M | 3.07 M | 1.83 M | 1.9 M | 1.97 M | 1.57 M | 1.62 M | 1.82 M | 2.02 M | 2.15 M | 2.38 M | 2.56 M | 2.73 M | 2.89 M | 3.05 M | 3.25 M | 3.4 M | 3.55 M | 3.69 M | 3.79 M | 1.85 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
25.1 M | 26.9 M | 27.7 M | 28.7 M | 29.8 M | 30.6 M | 32.5 M | 33.2 M | 33.4 M | 11.6 M | 12 M | 9.27 M | 34.7 M | 33.1 M | 34.6 M | 35 M | 28 M | 26 M | 29.6 M | 30.9 M | 29.1 M | 39.3 M | 34.6 M | 18.3 M | 18.4 M | 17.9 M | 18 M | 5.95 M | 36.2 M | 37.3 M | 34.7 M | 33.1 M | 7.57 M | 7.55 M | 6.33 M | 5.48 M | 7.14 M | 295 K | 284 K | 372 K | 358 K | 345 K | 372 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
49.4 M | 55.1 M | 55.1 M | 57.4 M | 55.4 M | 57.4 M | 54 M | 64.8 M | 52.2 M | 27.2 M | 32.1 M | 40.2 M | 62 M | 55.9 M | 52.9 M | 57 M | 47.8 M | 42.2 M | 46.3 M | 53.9 M | 46.9 M | 54.2 M | 49.1 M | 33.1 M | 31.1 M | 35.6 M | 38.6 M | 28.4 M | 75.1 M | 80 M | 70.9 M | 60.4 M | 29.8 M | 27.6 M | 20.2 M | 18.2 M | 17.1 M | 18.2 M | 18.2 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 1.56 M | 1.56 M | 1.56 M | 1.56 M | 1.46 M | 1.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
3.97 M | 3.98 M | 3.97 M | 3.94 M | 3.92 M | 3.91 M | 3.89 M | 3.89 M | 3.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.03 B | -1.01 B | -988 M | -968 M | -948 M | -933 M | -918 M | -903 M | -806 M | -799 M | -788 M | -771 M | -769 M | -740 M | -710 M | -682 M | -655 M | -635 M | -614 M | -595 M | -573 M | -551 M | -533 M | -505 M | -491 M | -481 M | -469 M | -454 M | -435 M | -380 M | -330 M | -292 M | -254 M | -221 M | -190 M | -159 M | -137 M | -159 M | -159 M | -90.9 M | -90.9 M | -90.9 M | -90.9 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -20.7 M | -20.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
216 M | 180 M | 199 M | 160 M | 176 M | 189 M | 198 M | 220 M | 182 M | 161 M | 174 M | 197 M | 218 M | 236 M | 230 M | 255 M | 268 M | 278 M | 227 M | 251 M | 263 M | 288 M | 161 M | 70.8 M | 71.9 M | 85 M | 96.8 M | 98.3 M | 160 M | 217 M | 253 M | 276 M | 176 M | 202 M | 221 M | 244 M | 261 M | 244 M | 244 M | 176 M | 176 M | 176 M | 176 M | 94.1 M | 94.1 M | 94.1 M | 94.1 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.4 M | 19.2 M | 28.7 M | 20 M | 25.3 M | 25.4 M | 30.4 M | 24.6 M | 47.7 M | 22.8 M | 35.8 M | 39.9 M | 39 M | 31.2 M | 44.7 M | 45.3 M | 61.7 M | 68.3 M | 36.3 M | 27.3 M | 53.6 M | 113 M | 35.3 M | 22.1 M | 25.4 M | 32.6 M | 54 M | 35.9 M | 29.9 M | 31.7 M | 34.2 M | 57 M | 26.6 M | 46 M | 54.9 M | 20.2 M | 60.1 M | 32.7 M | 23.7 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 9.85 M | 9.85 M | 9.85 M | 9.85 M | 10.8 M | 10.8 M | - | - | 9.59 M | - | - | - | 19 M | - | - | - | - | - | - | - |
Book Value |
167 M | 125 M | 144 M | 103 M | 120 M | 132 M | 144 M | 156 M | 130 M | 134 M | 142 M | 157 M | 156 M | 180 M | 177 M | 198 M | 220 M | 236 M | 180 M | 197 M | 217 M | 234 M | 112 M | 37.6 M | 40.8 M | 49.4 M | 58.2 M | 69.9 M | 85.3 M | 137 M | 182 M | 215 M | 146 M | 174 M | 200 M | 225 M | 244 M | 225 M | 225 M | 169 M | 169 M | 169 M | 169 M | 92.5 M | 92.5 M | 92.5 M | 92.5 M | 15.9 M | 15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
167 M | 125 M | 144 M | 103 M | 120 M | 132 M | 144 M | 156 M | 130 M | 134 M | 142 M | 157 M | 156 M | 180 M | 177 M | 198 M | 220 M | 236 M | 180 M | 197 M | 217 M | 234 M | 112 M | 37.6 M | 40.8 M | 49.4 M | 58.1 M | 69.9 M | 85.3 M | 137 M | 182 M | 215 M | 146 M | 174 M | 200 M | 225 M | 244 M | 225 M | 225 M | 169 M | 169 M | 169 M | 169 M | 92.5 M | 92.5 M | 92.5 M | 92.5 M | -20.8 M | -20.8 M | - | - | -9.16 M | - | - | - | -2.19 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aclaris Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
$ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M |  USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 57.1 | -0.14 % | $ 11 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.19 | -4.03 % | $ 6.51 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 11.24 | -2.01 % | $ 240 K | USA |
 |
SIGA Technologies
SIGA
|
$ 3.14 | -3.83 % | $ 225 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.68 | -7.49 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 94.9 | -3.91 % | $ 7.04 B | USA |
 |
Lipocine
LPCN
|
$ 1.59 | -7.85 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
$ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
$ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.95 | 2.73 % | $ 236 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
$ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
$ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.38 | -5.64 % | $ 36.4 M | Canada |
 |
Minerva Neurosciences
NERV
|
$ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
$ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
$ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
$ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
$ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
$ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
$ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
$ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
$ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
$ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
$ 8.23 | -1.79 % | $ 1.13 B | USA |